COMMENTARY

PMDA’s Seriousness About Becoming a Leading Global Regulatory Authority to Be Tested

May 30, 2013
The Pharmaceutical and Medical Devices Agency (PMDA) has compiled an “International Vision and Roadmap” as a future plan for its international activities. With “Global PMDA” as its catchphrase, the roadmap sets various urgent priorities for the coming years in areas…

To read the full story

COMMENTARY

By Takashi Ebisawa and Tatsuya Otsuka

Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…

By Takashi Ebisawa

Manufacturers of regenerative medicine-based products are beginning to differentiate themselves from competitors based not only on efficacy but also on the reduction of burdens on medical institutions where their therapies are provided.The procedures required for administering regenerative medicine products are…

By Yoshinori Sagehashi

Japan positions its new cost-effectiveness assessment (CEA) scheme merely as a tool to complement the current drug pricing system, but…

Tatsuya Kondo, chief executive of the Pharmaceuticals and Medical Devices Agency (PMDA), is hitting the exit at the end of…

Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…

By Reiji Anasako

With Japan’s tighter price control casting a chill over its pharma market, companies are setting their sights beyond the field of health insurance to carve out a new revenue stream, seeking opportunities in the business to tackle “mibyo” - a…